title: Attrition from HIV testing to antiretroviral therapy initiation among patients newly diagnosed with HIV in Haiti.
abstract: OBJECTIVE
  We report rates and risk factors for attrition in the first cohort of patients followed through all stages from HIV testing to antiretroviral therapy (ART) initiation.
  
  
  METHODS
  Cohort study of all patients diagnosed with HIV between January and June 2009.
  
  
  METHODS
  We calculated the proportion of patients who completed CD4 cell counts and initiated ART or remained in pre-ART care during 2 years of follow-up and assessed predictors of attrition.
  
  
  RESULTS
  Of 1427 patients newly diagnosed with HIV, 680 (48%) either initiated ART or were retained in pre-ART care for the subsequent 2 years. One thousand eighty-three patients (76%) received a CD4 cell count, and 973 (90%) returned for result; 297 (31%) had CD4 cell count <200 cells per microliter, and of these, 256 (86%) initiated ART. Among 429 patients with CD4 >350 cells per microliter, 215 (50%) started ART or were retained in pre-ART care. Active tuberculosis was associated with not only lower odds of attrition before CD4 cell count [odds ratio (OR): 0.08; 95% confidence interval (CI): 0.03 to 0.25] but also higher odds of attrition before ART initiation (OR: 2.46; 95% CI: 1.29 to 4.71). Lower annual income (≤US $125) was associated with higher odds of attrition before CD4 cell count (OR: 1.65; 95% CI: 1.25 to 2.19) and before ART initiation among those with CD4 cell count >350 cells per microliter (OR: 1.74; 95% CI: 1.20 to 2.52). After tracking patients through a national database, the retention rate increased to only 57%.
  
  
  CONCLUSIONS
  Fewer than half of patients newly diagnosed with HIV initiate ART or remain in pre-ART care for 2 years in a clinic providing comprehensive services. Additional efforts to improve retention in pre-ART are critically needed.
authors.affiliation: Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections, Port-au-Prince, Haiti.
authors.forename: Edva
authors.initials: E
authors.lastname: Noel
authors.forename: Morgan
authors.initials: M
authors.lastname: Esperance
authors.forename: Megan
authors.initials: M
authors.lastname: McLaughlin
authors.forename: Rachel
authors.initials: R
authors.lastname: Bertrand
authors.forename: Jessy
authors.initials: J
authors.lastname: Devieux
authors.forename: Patrice
authors.initials: P
authors.lastname: Severe
authors.forename: Diessy
authors.initials: D
authors.lastname: Decome
authors.forename: Adias
authors.initials: A
authors.lastname: Marcelin
authors.forename: Janet
authors.initials: J
authors.lastname: Nicotera
authors.forename: Chris
authors.initials: C
authors.lastname: Delcher
authors.forename: Mark
authors.initials: M
authors.lastname: Griswold
authors.forename: Genevive
authors.initials: G
authors.lastname: Meredith
authors.forename: Jean William
authors.initials: JW
authors.lastname: Pape
authors.forename: Serena P
authors.initials: SP
authors.lastname: Koenig
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006205:Haiti; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010349:Patient Compliance; D010352:Patient Dropouts / Q000706:statistics & numerical data*; D055815:Young Adult